Feedback from Stakeholders

Some important aspects of the feedback considered in the development of final prototypes were as follows:

1. Patients need to be told about risk but terms like “moderate risk” could be unclear. Alternative words need to be explored at the focus groups.
2. Reporting formats should encourage “buy-in” from patients and give them opportunities to teach back to doctors about what they have been told. Focus groups should elicit methods that are preferred by patients.
3. Reporting formats need clear statements on them “About the Test” e.g. is it a 3 month review
4. Information on the sample reports needs to be well based in fact.
5. Need to remember that low values for HbA1c are also problematic.
6. Reports should not have too much information or be too crowded.
7. Consideration should be given to the impact of having a “yellow zone” and whether this encouraged inaction.
8. Each stakeholder had their own preferences for different information presentation from a choice of a metre, a line graph and a range of photos.
9. Stakeholders questioned the use of harsh or scary language and the likely impact.
10. Tests results need to consider personalised issues such as the fact that HbA1c targets are modified for things like duration of disease, type of medication, co-morbidities.
11. Need a patient pathology summary, which includes multiple tests.

Based on the feedback obtained during the eye-tracking experiments and the stakeholder consultation, two sample prototypes were proposed for Arabic speaking groups and English speaking groups. Items 1-9 (above) were considered in the final prototypes that were taken to the focus groups, 10 and 11 were not considered feasible at this stage.